Emma Walmsley said GSK has nearly doubled its organic R&D spending since she became CEO.
“since I've been in this job, I think we've nearly doubled our R D spend, uh, organically.”
Person
Emma Walmsley
1 episodes · 22 quoted claims
Walmsley said GSK expects to launch fourteen scale medicines and vaccines this decade, each with potential sales above 2 billion pounds.
“a cohort of, we think, fourteen scale medicines and vaccines, each of the potential of more than 2 billion pounds worth of sales that we expect to launch this decade.”
Walmsley said multiple myeloma, a blood cancer, has about 180,000 new diagnoses each year.
“in multiple myeloma, a very nasty blood cancer that, uh, where there are 180,000 new diagnoses every year.”
Walmsley said GSK may have a new functional cure for hepatitis B, a disease affecting 250 million people worldwide.
“we may have a new functional cure for a horrible disease, hepatitis B, um, which impacts 250 million people around the world.”
Walmsley said chronic obstructive pulmonary disease (COPD), which Trelegy treats, is the third leading cause of death in the world.
“chronic obstructive pulmonary disease. Perhaps many haven't heard of it, but it's the third leading cause of death in the world.”
Walmsley said GSK's long-acting HIV treatment is an injection taken six times a year, with plans to reduce that to four and eventually fewer.
“So that means an injection you can take six times a year.”
Walmsley said GSK's shingles vaccine gives 90% protection for at least eleven years.
“gives 90% protection for at least eleven years, you know, one in three of us”
Walmsley said she has served on Microsoft's board for six years.
“Great privilege that that is, and I have been for six years.”
Walmsley said about 90% of drug assets fail across the pharmaceutical industry.
“90% of, um, and this is industry writ large, 90% of, uh, the assets, uh, fail.”
Walmsley said analysing infectious-disease patterns around the world accelerated GSK's RSV vaccine outcomes by two years by allowing trials to close earlier.
“outcomes by two years because we were able to look at the infectious disease patterns in different parts of the globe”
Walmsley said GSK used the genetic marker dMMR, learned in endometrial cancer, to target colorectal cancer trials more precisely.
“Actually, we looked at a particular um, uh, genetic marker called D M M R, um, which, uh, allowed us to be much more precise”
Walmsley said that of 278 medicines centrally approved in Europe in 2022, about 40% were not yet available in Norway.
“of the 278, I think it was, uh, medicines, uh, this is in 2022 that were centrally approved in Europe, 40% of them are not yet available in Norway.”
Walmsley said GSK announced another 800 million in US medicine and vaccine manufacturing investment in the prior year.
“Um, last year we announced another 800 million that we're spending in in both medicine and vaccine, um, manufacturing in the U. S.”
Walmsley said antimicrobial resistance could kill about 38 million people by 2050 unless more antibiotics are developed.
“I think it's 38 million people by twenty fifty unless we develop more antibiotics.”
Walmsley said there has been no new antibiotic for uncomplicated urinary tract infections in twenty years, and GSK hoped to get one approved.
“We haven't had a new antibiotic for twenty years.”
Walmsley said GSK's balance sheet was a major challenge when she became CEO and was part of the reason for the demerger of its consumer business, Haleon.
“balance sheet, which was a major challenge when we when we came in, which is part of the reason why we did the demerger of hailion.”
Walmsley said GSK's consumer division was built through two global joint ventures, first with Novartis's portfolio and then with Pfizer's.
“we went through two massive global joint ventures, firstly with Novartis's portfolio and integrations, frankly, uh, and then with Pfizer's.”
Walmsley said GSK upgraded its 2031 outlook a second time, adding 7 billion over four years, implying 17 billion of sales growth this decade.
“we've added another 7 billion to the outlook. Just in four years. That means we'll grow 17 billion this decade in sales”
Walmsley said GSK had about 100,000 employees when she started as CEO and about seventy thousand at the time of the interview.
“at the beginning it was 100,000 people, we're now seventy or so.”
Walmsley said GSK employs about 15,000 scientists.
“the energy with which 15,000 scientists get up to do the near impossible.”
Walmsley said GSK donated about 440 million doses of a drug for lymphatic filariasis, a neglected tropical disease, in the prior year.
“I think 440 million donations of doses, um, of a drug that's for, uh, a neglected tropical disease in in Africa, which we've called lymphatic filariasis”
Walmsley said she grew up in a military family and her father served in the Navy for his whole career.
“I grew up in a military family, so my father was in the Navy his whole career.”